Previous 10 | Next 10 |
2023-05-05 08:57:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmace...
2023-05-05 08:26:55 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nanobiotix (NASDAQ: NBTX ) stock is taking off on Friday after the company revealed details about ongoing contract negotiations for NBTXR3 . NBTXR3 is Nanobiotix’...
2023-05-05 07:34:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re diving into the biggest pre-market stock movers traders will want to keep an eye on Friday morning! Moving stocks today are earnings reports, investments, and more. Let...
2023-04-29 18:15:06 ET Nanobiotix S.A. (NBTX) Q4 2022 Results Conference Call April 25, 2023 08:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder and CEO Bart Van Rhijn - CFO Conference Call Participants Jonathan Miller - Ev...
2023-04-25 13:30:38 ET Gainers: CXApp ( CXAI ) +82% . Petros Pharmaceuticals ( PTPI ) +49% . LogicMark ( LGMK ) +28% . Apollomics ( APLM ) +23% . The Aaron's Company ( AAN ) +18% . Baudax Bio ( BXRX ) +18% . Predi...
2023-04-25 02:55:08 ET Nanobiotix press release ( NASDAQ: NBTX ): FY GAAP EPS of -€1.64. As of December 31, 2022, Nanobiotix had €41.4 million in cash and cash equivalents, compared to €83.9 million as of December 31, 2021. Based on the curre...
Pivotal Phase 3 trial NANORAY-312 ongoing globally with 104 sites activated in 25 countries to date; interim efficacy analysis after 67% of planned progression free survival (PFS) events expected in H2 2024, as planned Final data from Study 102 in head and neck cancer expected in H2 2023 ...
Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April 25, 2023 PARIS and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “ Company ”), a late-stage clinical biotechnology com...
2023-03-27 16:42:41 ET Nanobiotix ( NASDAQ: NBTX ) is postponing its full-year 2022 financial results, which was originally scheduled for release on Tuesday. The biotech said it would announce the results at a later date to give it more time to complete its year-end clos...
PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...